Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd (TLSA) Covered Calls
As of September 21, 2026, TLSA has 3 covered call opportunities in the coming three months. Return ranges from 183.3 to 461.1% until expiration. Annualized return ranges from 385.2 to 940.3%. The nearest expiration is December 18, 2026. Maximum potential profit is $415.
Read more
Running TLSA covered calls helps you generate consistent income from Tiziana Life Sciences Ltd's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Tiziana Life Sciences Ltd involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best TLSA covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if TLSA stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling TLSA covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Tiziana Life Sciences Ltd covered call is worth writing.
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients.
The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Income-focused investors, long-term TLSA holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling TLSA covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Tiziana Life Sciences Ltd covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile25.00% Subdued
- Market cap (M$)116
- 52 weeks high-61.70%
- 52 weeks low18.42%
- Analyst recommendationStrong Buy
1.00 - Target price$7.98
802.30% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-09-18
- P/E—
- Future P/E—
- EPS (ttm)-0.16
- EPS growth next 5 years-5.27%
As of September 21, 2026
| 2027-03-19 | 179 | 5.00 | 455.56 | 0.05 | 5.00 | 415.00 | 461.11 | 940.25 | -5.56 | +1.00 | 0 | 4.95 |
| 2026-12-18 | 88 | 2.50 | 177.78 | 0.05 | 0.10 | 165.00 | 183.33 | 760.42 | -5.56 | +0.24 | 2,235 | 0.05 |
| 2027-03-19 | 179 | 2.50 | 177.78 | 0.10 | 0.20 | 170.00 | 188.89 | 385.16 | -11.11 | +0.36 | 2,713 | 0.10 |
As of September 21, 2026
Sell covered calls with the data behind you
Find the best TLSA covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→